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treatment with lornoxicam. Positive effect achieved by intramuscular administration of the drug. 3 patients with a disease 
period of more than 10 years had the initial intramuscular treatment combined with a single intravenous administration.  
Conclusions. The use of lornoxicam eliminates acute pain caused by gouty arthritis within 4-6 days of treatment at a 
dose of 16 mg per day. Administration of lornoxicam intramuscularly twice daily at a dose of 8 mg with 8 hours intervals 
provides guaranteed pain relief in acute gouty arthritis.  
 
THE CONTRIBUTION OF PRO-INFLAMMATORY INTERLEUKIN-6 IN THE DEVELOPMENT OF CARDIOMYOPATHY 
IN TYPE 2 DIABETES IN PATIENTS WITH INCREASED BODY WEIGHT 
Khushboo K., Sokolnikova N. V.  
Scientific adviser: Prof. Zhuravlyova L. V.  
Kharkiv National Medical University,  
Kharkiv, Ukraine  
Department of Internal Medicine №3 and Endocrinology 
Introduction. According to statistics from the World Health Organization, the number of patients with diabetes has 
increased 4 times and continues to grow steadily. Hyperglycemia causes an increased risk of cardiovascular disease, 
including myocardial pathology, regardless of concomitant vascular causes.  
The development of cardiomyopathy (CMP) in patients with type 2 diabetes mellitus (DM-2), especially those with 
increased body weight, is determined by changes in the metabolism of visceral adipose tissue, which increases the level 
of factors that increase insulin resistance - tumor necrosis factor-α, interleukin-6 (IL-6) and others.  
The aim of the study. Was to determine the effect of IL-6 on the formation of CMP in patients with DM-2 with normal 
and overweight.  
Materials and methods. The study is a fragment of research of the Department of Internal Medicine № 3 and 
endocrinology of KhNMU "Diabetes mellitus and problems of comorbid pathology". We examined 102 patients with DM-2 
(duration of diabetes from 1 to 9 years without severe diabetic complications). The control group consisted of 20 healthy 
volunteers, comparable in age and gender.  
In all patients and controls, body mass was measured, height was measured, and body mass index (BMI) was 
calculated. The content of IL-6 was determined by ELISA using Vector-Best reagent kits. An echocardiographic method 
was used to measure diastolic function of the left ventricular myocardium as a marker of myocardial lesion in diabetes. 
The maximum peak of diastolic filling was determined with rapid filling of the left ventricle E, the maximum peak of the 
rate of atrial filling of the left ventricle during left atrial systole A, and the E/A ratio.  
Results. The first group included patients with DM-2 and BMI below 24.99 kg/m2 (n=20). Patients with BMI above 25.0 
kg/m2 were allocated to group 2 (n=82). IL-6 (pg/ml) in the control group was 8.83±0.22; in the 1st group - 10.02±0.26; in 
group 2, 13.78±0.24 and significantly differed in groups (p≥0.05). The indicator E (ms) in the control group was 
0.71±0.01; in the 1st group 0.63±0.01; in the 2nd group 0.58±0.006. The E/A ratio in the control group was 1.4±0.075; in 
the 1st 0.94±0.03, in the 2nd - 0.81±0.022 and differed significantly in the groups (p≥0.05). A correlation between the 
level of proinflammatory IL-6 and the E/A ratio was found in patients in group 2 (R=-0.285 (p≥0.05)). No significant 
correlations were found in patients of group 1 and healthy volunteers.  
Conclusion. Adipokine IL-6 as a mediator of inflammation contributes significantly to the development of diastolic 
dysfunction, which is the primary link in the pathogenesis of heart failure in patients with DM-2. 
The data of our study confirm the effect of IL-6 on the formation of CMP in patients with DM-2 and require further in-
depth study of this problem.  
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Relevance. It is known that disorders of lipid metabolism in patients with diabetic nephropathy (DN) lead to decreasing of 
kidney function and increasing risk of cardiovascular disorders. According to a number of studies, low high-density 
lipoproteins and increased level of triglycerides are independent risk factors in the general population.  
Purpose of the study. Evaluate the potency of fenofibrate in the treatment of patients with diabetic nephropathy.  
Materials and methods. 47 patients with DN and dyslipidemia were divided into 2 groups. Patients in the first group (19 
women and 7 men, 57.4 ± 2.3 years old) were treated with basic therapy. In the second group (12 women and 9 men, 
52.8 ± 1.4 years old), fenofibrate was additionally prescribed at a dose of 145 mg per day for 6 months. Doppler 
ultrasound of the kidneys and heart was performed to evaluate the results of treatment (Evaluation of treatment 
outcomes were conducted on the results of Doppler ultrasound of the kidneys and heart ) 
Research results. Based on the results of patient’s treatment who were receiving basic therapy, proteinuria level 
significantly decreased from (0.156 ± 0.070) g / l to (0.070 ± 0.029) g / l (p <0.05). In the group of patients receiving 
fenofibrate, protein loss with urine decreased from (0.28 ± 0.058) g / l to (0.059 ± 0.030) g / l per day and was statistically 
significantly lower than in the first group (p <0.05) . Conducting an ultrasound examination in patients in this group 
showed a significant decrease of the renal vascular resistance (RI) index from (0.75 ± 0.050) to (0.63 ± 0.050), (p <0.02), 
and a tendency of improving transmitral blood flow, namely, a decrease of IVRT from (105,436 ± 2,040) ms to (93,270 ± 
4,029) ms (p <0.05) and an increase of the Ve: Va correlation from (0.854 ± 0.025) to (1.250 ± 0.040), but this was not 
statistically significant (p = 0.062). These effects of fenofibrate can be explained by the following: fenofibrate is an 
agonist of the activated peroxisome proliferator (PPAR). It was found that both PPAR and cytochrome P450 4A are 
expressed in the proximal tubules of the kidneys. Treatment with PPAR agonists increases the content of cytochrome 
P450 4A protein and the production of 20-hydroxyarachidonic acid, and thus, fenofibrate can improve blood flow, 
restoring the action of cytochrome P450-dependent arachidonic acid hydroxylase.  
